Evidence map›Paper›PMID 39507885›Full record

Trial reportOpen forum infectious diseases2024

Efficacy and Safety of Dolutegravir Plus Emtricitabine vs Combined Antiretroviral Therapy for the Maintenance of HIV Suppression: Results Through Week 144 of the SIMPL'HIV Trial.

Annalisa Marinosci, Delphine Sculier, Gilles Wandeler, Sabine Yerly, Marcel Stoeckle, Enos Bernasconi, Dominique L Braun, Pietro Vernazza, Matthias Cavassini, Laurent Decosterd and 6 more

Abstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Open forum infectious diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Annalisa MarinosciHIV/AIDS Unit, Division of Infectious Diseases, Geneva University Hospitals, and the University of Geneva Faculty of Medicine, Geneva, Switzerland.ORCID https://orcid.org/0000-0002-8054-0044
Delphine SculierHIV/AIDS Unit, Division of Infectious Diseases, Geneva University Hospitals, and the University of Geneva Faculty of Medicine, Geneva, Switzerland.
Gilles WandelerDivision of Infectious Diseases, Bern University Hospital, University of Bern, Bern, Switzerland.ORCID https://orcid.org/0000-0002-5278-8763
Sabine YerlyLaboratory of Virology, Geneva University Hospitals, Geneva, Switzerland.
Marcel StoeckleDivision of Infectious Diseases and Hospital Epidemiology, University Hospital of Basel, University of Basel, Basel, Switzerland.
Enos BernasconiDivision of Infectious Diseases, Ente Ospedaliero Cantonale, Lugano, Switzerland.ORCID https://orcid.org/0000-0002-9724-8373
Dominique L BraunDepartment of Infectious Diseases and Hospital Epidemiology, University Hospital of Zurich, University of Zurich, Zurich, Switzerland.
Pietro VernazzaDivision of Infectious Diseases and Hospital Epidemiology, Kantonspital St. Gallen, St. Gall, Switzerland.
Matthias CavassiniDivision of Infectious Diseases, University Hospital of Lausanne, Lausanne, Switzerland.ORCID https://orcid.org/0000-0003-0933-7833
Laurent DecosterdLaboratory of Clinical Pharmacology, Department of Laboratory Medicine and Pathology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
Huldrych F GünthardDepartment of Infectious Diseases and Hospital Epidemiology, University Hospital of Zurich, University of Zurich, Zurich, Switzerland.
Patrick SchmidDivision of Infectious Diseases and Hospital Epidemiology, Kantonspital St. Gallen, St. Gall, Switzerland.ORCID https://orcid.org/0000-0003-1978-5082
Andreas LimacherCTU Bern, University of Bern, Bern, Switzerland.
Mattia BrancaCTU Bern, University of Bern, Bern, Switzerland.ORCID https://orcid.org/0000-0002-8063-7882
Alexandra CalmyHIV/AIDS Unit, Division of Infectious Diseases, Geneva University Hospitals, and the University of Geneva Faculty of Medicine, Geneva, Switzerland.
Swiss HIV Cohort Study

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The SIMPL'HIV study investigated whether switching to dolutegravir (DTG) + emtricitabine (FTC) was noninferior to continuing combined antiretroviral therapy for maintaining HIV-1 suppression at 144 weeks. The study demonstrated that viral suppression, CD4 gains, adverse events, quality of life, and patient satisfaction were comparable between groups, confirming DTG + FTC's safety and efficacy for long-term management of HIV-1 infection.

Indexed as

dolutegravir + emtricitabineHIV-1 dual therapymaintenance treatmentpatient satisfactionquality of life

Identifiers

PMID39507885
PMCPMC11540136

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.